Correction to: British Journal of Cancer (2016) 114, 45–52. doi:https://doi.org/10.1038/bjc.2015.426; published online 10 December 2015
The first author of this article is incorrectly listed as Anne-Sophie Hamy-Petit in the original article and should be Anne-Sophie Hamy.
This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.
Change history
20 March 2018
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at https://doi.org/10.1038/bjc.2015.426
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
About this article
Cite this article
Hamy, AS., Belin, L., Bonsang-Kitzis, H. et al. Erratum: Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer 118, e14 (2018). https://doi.org/10.1038/bjc.2018.4
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2018.4
This article is cited by
-
Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China
Journal of Cancer Research and Clinical Oncology (2018)
